Travere Therapeutics (NASDAQ:TVTX) CEO Eric Dube Sells 95,666 Shares

Travere Therapeutics, Inc. (NASDAQ:TVTX) CEO Eric Dube sold 95,666 shares of the stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $62.26, for a total value of $5,956,165.16. Following the sale, the chief executive officer owned 432,886 shares of the company’s stock, valued at $26,951,482.36. This trade represents a 18.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Travere Therapeutics Stock Performance

TVTX opened at $64.74 on Friday. The firm has a market cap of $6.10 billion, a PE ratio of -140.74 and a beta of 1.05. The company has a quick ratio of 3.99, a current ratio of 4.05 and a debt-to-equity ratio of 24.58. The business has a fifty day simple moving average of $61.63 and a 200-day simple moving average of $48.50. Travere Therapeutics, Inc. has a fifty-two week low of $22.06 and a fifty-two week high of $68.73.

Travere Therapeutics (NASDAQ:TVTX) last announced its earnings results on Tuesday, August 4th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.03. Travere Therapeutics had a negative return on equity of 55.15% and a negative net margin of 7.35%.The company had revenue of $169.58 million for the quarter, compared to analyst estimates of $157.27 million. During the same period in the previous year, the firm earned $0.13 earnings per share. Travere Therapeutics’s revenue for the quarter was up 48.2% compared to the same quarter last year. As a group, equities analysts predict that Travere Therapeutics, Inc. will post -0.54 EPS for the current fiscal year.

Trending Headlines about Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: Brokerages have assigned Travere Therapeutics a consensus rating of “Moderate Buy,” indicating that analysts generally continue to see upside potential in the stock. Travere Therapeutics Given Consensus Rating of Moderate Buy by Brokerages
• Neutral Sentiment: Company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 24. The event could provide updates on Travere’s rare-disease pipeline and commercial outlook, but no new operating information was announced. Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
• Negative Sentiment: Multiple insiders, including the CEO, CFO, CAO and EVPs, reduced their holdings, with individual ownership declines ranging from about 7% to 60%. Although the sales were prearranged, concentrated insider selling may raise questions about near-term sentiment and limit the stock’s momentum.

Institutional Trading of Travere Therapeutics

Hedge funds have recently made changes to their positions in the stock. GAMMA Investing LLC grew its position in Travere Therapeutics by 53.4% during the second quarter. GAMMA Investing LLC now owns 606 shares of the company’s stock valued at $34,000 after purchasing an additional 211 shares in the last quarter. Corient Private Wealth LP lifted its position in Travere Therapeutics by 1.4% in the 2nd quarter. Corient Private Wealth LP now owns 48,125 shares of the company’s stock worth $2,734,000 after buying an additional 648 shares in the last quarter. ProShare Advisors LLC lifted its position in Travere Therapeutics by 4.1% in the 4th quarter. ProShare Advisors LLC now owns 19,007 shares of the company’s stock worth $726,000 after buying an additional 756 shares in the last quarter. Allworth Financial LP acquired a new stake in shares of Travere Therapeutics during the 2nd quarter valued at $47,000. Finally, Swiss National Bank boosted its stake in shares of Travere Therapeutics by 0.6% during the 1st quarter. Swiss National Bank now owns 168,100 shares of the company’s stock valued at $4,994,000 after buying an additional 1,000 shares during the period.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Guggenheim upped their price objective on shares of Travere Therapeutics from $65.00 to $75.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Evercore set a $78.00 price target on shares of Travere Therapeutics in a report on Monday, August 10th. Wells Fargo & Company upped their price target on shares of Travere Therapeutics from $50.00 to $65.00 and gave the company an “overweight” rating in a research report on Friday, June 12th. Canaccord Genuity Group raised their price objective on shares of Travere Therapeutics from $62.00 to $70.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Finally, TD Cowen lifted their price objective on shares of Travere Therapeutics from $60.00 to $75.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $68.00.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare kidney and immune-mediated diseases. The company’s work is centered on conditions with significant unmet medical needs, including diseases that can lead to progressive kidney damage and kidney failure.

Travere’s principal commercial product is FILSPARI (sparsentan), an oral therapy for adults with primary immunoglobulin A nephropathy, or IgA nephropathy, who are at risk of disease progression.